

FIGURE 1

(A) CDR sequences of antibody 645

CDRH1 GIDLSNYAIN (SEQ ID NO: 71)

CDRH2 IIWASGTTFYATWAKG (SEQ ID NO: 72)

CDRH3 TVPGYSTAPYFDL (SEQ ID NO: 73)

CDRL1 QSSPSVWSNFLS (SEQ ID NO: 74)

CDRL2 EASKLTS (SEQ ID NO: 75)

CDRL3 GGGYSSISDTT (SEQ ID NO: 76)

(B) Ab 645 VH-region (unmutated, i-e without cysteine engineered for a disulphide bond) (SEQ ID NO: 77)

EVQLLES^{GGGLVQPGGSLRL}SCAVSGIDLSNYAINWVRQAPGK^{GLEWIGIIWASGTTFYATWAKGRFT}
ISRDN^{SKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGT}LVTVSS

(C) Ab 645 VH-region (mutated, i-e with a cysteine engineered for a disulphide bond, underlined) (SEQ ID NO: 78)

EVQLLES^{GGGLVQPGGSLRL}SCAVSGIDLSNYAINWVRQAPGK^{CLEWIGIIWASGTTFYATWAKGRFT}
ISRDN^{SKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGT}LVTVSS

(D) Ab 645 VL-region (unmutated, i-e without cysteine engineered for a disulphide bond) (SEQ ID NO: 79)

DIQMTQSPSSVSASVGD^{RVTTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSR}FSGSGS
GTDFTLT^{ISSLPEDFATYYCGGGYSSISDTTFGG}GTKVEIK

(E) Ab 645 VL-region (mutated, i-e with a cysteine engineered for a disulphide bond, underlined) (SEQ ID NO: 80)

DIQMTQSPSSVSASVGD^{RVTTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSR}FSGSGS
GTDFTLT^{ISSLPEDFATYYCGGGYSSISDTTFGC}GTKVEIK

FIGURE 1 continued

(F) 645 scFv (VH/VL) (unmutated, i-e without cysteines engineered for a disulphide bond) (SEQ ID NO: 81)

EVQLLES^{GGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGK}GLEWIGIIWASGTTFYATWAKGRFT
ISRDN^{SKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGT}LVTVSSGGGSGGGGSGGGGS
GGGGSDIQMTQSPSSVSASVGDRVTITCQSSPSVWSN^{FLSWYQQKPGKAPKLLIYEASKLTSGVPSRF}
SGSGSGTDFTLTIS^{SLQPEDFATYYCGGYS}ISD^{TTFGG}TKVEIK

(G) 645 dsscFv (VH/VL) (mutated, with cysteines engineered for a disulphide bond, underlined)
(SEQ ID NO: 82)

EVQLLES^{GGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGK}CLEWIGIIWASGTTFYATWAKGRFT
ISRDN^{SKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGT}LVTVSSGGGSGGGGSGGGGS
GGGGSDIQMTQSPSSVSASVGDRVTITCQSSPSVWSN^{FLSWYQQKPGKAPKLLIYEASKLTSGVPSRF}
SGSGSGTDFTLTIS^{SLQPEDFATYYCGGYS}ISD^{TTFGC}GTKVEIK

FIGURE 2

FIG. 2A




FIG. 2B




FIGURE 3









Sample Name	Antibody Construct	Light Chain Dimer
Wittrup 01		
	dsscFv-1 dsscFv-1	
Wittrup 02		
	dsscFv-2 dsscFv-2	
TrYbe 03		
	dsscFv-1 dsscFv-3B	
TrYbe 04		
	dsscFv-1 dsscFv-3A	

FIGURE 3 continued





Sample Name	Antibody Construct	Light Chain Dimer
TrYbe 05	 dsscFv-3B dsscFv-1	 dsscFv-1 dsscFv-1
TrYbe 06	 dsscFv-3A dsscFv-1	 dsscFv-1 dsscFv-1

FIGURE 4





FIGURE 5




FIGURE 5 continued




FIGURE 6





FIGURE 6 continued




FIGURE 7





FIGURE 7 continued




FIGURE 8

FIG. 8A




FIG. 8B

